Healthcare
Amorphous Solid Dispersion (ASD)
Solubility enhancement of poorly soluble APIs.

Amorphous solid dispersion is a technology for solubility enhancement of drugs. Solubility of a large number of APIs is limited by their crystalline nature which results in poor solubility. If the absorption in the GI tract is acceptable, these compounds are classified as BCD class II. By dispersing the drug on a molecular level in a polymeric carrier, an amorphous state of the API is maintained in the drug product overcoming solubility issues. Shin-Etsu AQOAT® HPMCAS is the leading excipient in solubility enhancement by amorphous solid dispersion technology. Also PHARMACOAT® and HPMCP show good results in solubility enhancement.